Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...

Dozens of drugs can alter the immune system and affect activity of immune checkpoint inhib ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have produced ...

For women with higher-risk breast cancer, 3 days of radiotherapy might enhance the immune response to checkpoint inhibitors.

Immune checkpoint inhibitor (ICI) pneumonitis is a potentially life-threatening immune-related adverse event associated with ICI therapy across various malignancies. ICIs enhance antitumour immunity ...

Use of Ablative Radiotherapy in the Setting of Oligometastatic Disease A retrospective analysis of 3,626 patients treated with ICIs for various malignancies within a single health system was conducted ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy. (HealthDay News) — Patients with cancer aged 65 years and older receiving immune ...